Phase II trial Combining Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Men with Metastatic Castration-Resistant Prostate Cancer

Dr. Yang-Min Ning and collaborators reported, in the April 20, 2010 issue of the Journal of Clinical Oncology, a Phase II trial which combined chemotherapy (docetaxel) with an anti-angiogenesis drug for men with castration-resistant prostate cancer (CRPC). The data suggests that such a combination is more effective than chemotherapy alone. […]

Chemotherapy, Combining Drugs to Extend Life

The continuing search for effective treatments for men with hormone refractory prostate cancer (HRPC) has been a long and not very successful story. To date, under scientific conditions, the only chemotherapy which has demonstrated any survival benefit for men with prostate cancer has been docetaxel with prednisone. However, the survival benefit is very limited, only [...]